Natasha A. Winter

Natasha A. Winter

Auto-generated profile, based on publicly available information

Natasha A. Winter

National Health and Medical Research Council Centre for Research Excellence in Severe Asthma, Newcastle, NSW, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
EMEleanor Majellano
Eleanor Majellano
VCVanessa Clark
Vanessa Clark
NWNatasha A Winter
Natasha A Winter
PGPeter G Gibson
Peter G Gibson
VMVanessa M McDonald
Vanessa M McDonald
Asthma is a chronic condition with great variability. It is characterized by intermittent episodes of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness. Asthma severity varies uniquely between individuals and may change over time. Stratification of asthma severity is an integral part of asthma management linking appropriate treatment to establish asthma control. Precision assessment of severe asthma is crucial for monitoring the health of people with this disease. The literature suggests multiple factors that impede the assessment of severe asthma, these can be grouped into health care professional, patient and organizational related barriers. These barriers do not exist in isolation but interact and influence one another. Recognition of these barriers is necessary to promote precision in the assessment and management of severe asthma in the era of targeted therapy. In this review, we discuss the current knowledge of the barriers that impede assessment in severe asthma and recommend potential strategies for overcoming these barriers. We highlight the relevance of multidimensional assessment as an ideal approach to the assessment and management of severe asthma.

1 January 2021 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
NWNatasha A. Winter
Natasha A. Winter
PGpeter gibson
peter gibson
MFMichael Fricker
Michael Fricker
JSJodie L. Simpson
Jodie L. Simpson
PWPeter Wark
Peter Wark
VMVanessa M McDonald
Vanessa M McDonald
Winter NA, et al. Allergy Asthma Immunol Res. 2021 May;13(3):450-467. https://doi.org/10.4168/aair.2021.13.3.450

1 July 2021 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
NWNatasha A Winter
Natasha A Winter
PGPeter G Gibson
Peter G Gibson
VMVanessa M McDonald
Vanessa M McDonald
MFMichael Fricker
Michael Fricker
Purpose: The clinical and inflammatory associations of mast cells (MCs) and basophils in chronic obstructive pulmonary disease (COPD) are poorly understood. We previously developed and validated a qPCR-based MC/basophil gene signature in asthma to measure these cells in sputum samples. Here, we measured this gene signature in a COPD and control population to explore the relationship of sputum MCs/basophils to inflammatory and COPD clinical characteristics. Patients and Methods: MC/basophil signature genes (TPSAB1/TPSB2, CPA3, ENO2, GATA2, KIT, GPR56, HDC, SOCS2) were measured by qPCR in sputum from a COPD (n=96) and a non-respiratory control (n=17) population. Comparative analyses of gene expression between the COPD and the control population, and between eosinophilic COPD and non-eosinophilic COPD were tested. Logistic regression analysis and Spearman correlation were used to determine relationships of sputum MC/basophil genes to inflammatory (sputum eosinophil proportions, blood eosinophils) and clinical (age, body mass index, quality of life, lung function, past year exacerbations) characteristics of COPD. Results: MC/basophil genes were increased in COPD versus control participants (CPA3, KIT, GATA2, HDC) and between eosinophilic-COPD and non-eosinophilic COPD (TPSB2, CPA3, HDC, SOCS2). We found all MC/basophil genes were positively intercorrelated. In COPD, MC/basophil genes were associated with eosinophilic airway inflammation (GATA2, TPSB2, CPA3, GPR56, HDC, SOCS2), blood eosinophilia (all genes) and decreased lung function (KIT, GATA2, GPR56, HDC). Conclusion: We demonstrate associations of MCs and basophils with eosinophilic inflammation and lower lung function in COPD. These findings are consistent with prior results in asthma and may represent a new tool for endotyping eosinophilic-COPD.